Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025




Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains Sol-Gel’s audited annual financial statements for 2025, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at https://ir.sol-gel.com/financials/sec-filings. The Company will deliver a hard copy of its 2025 annual report on Form 20-F, including its complete audited financial statements, free of charge to its shareholders, upon request to Eyal Ben-Or, Chief Financial Officer, at Eyal.Ben-Or@sol-gel.com.

Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.

To learn more about Sol-Gel, visit www.sol-gel.com

Sol-Gel Investor Relations:
Eyal Ben-Or
Chief Financial Officer
ir@sol-gel.com

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder




Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

This positive progress follows the Company’s recent announcement on March 11, 2026, regarding the advancement of participant enrollment for the third cohort at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. Patients at the prestigious U.S. institutions – Yale University and Johns Hopkins University – continue to progress successfully through their treatment protocol, demonstrating continued safety and tolerability with no serious adverse events reported to date.

The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The successful ongoing treatment at these leading U.S. medical centers reflects strong momentum and confidence in CMND-100 as a potential breakthrough therapy for AUD.

“Building on the encouraging recruitment momentum and positive topline results from prior cohorts, we are pleased with the successful continuation of treatment in our U.S. clinical sites,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration

Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration




Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration

Achievement marks advancement of novel obesity target identified through Convergence™ AI platform


EMERYVILLE, Calif.–(BUSINESS WIRE)–Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its strategic obesity discovery collaboration with Eli Lilly and Company (Lilly), initiated in December, 2023.

The designated target, identified using Fauna Bio’s proprietary Convergence™ AI platform, represents a potential first-in-class approach to treating obesity by leveraging insights from hibernating mammals that naturally regulate body weight and metabolism. This milestone triggers a payment to Fauna Bio under the terms of the collaboration agreement,.

“This target designation validates the power of our Convergence™ platform to identify truly novel biology in metabolic disease,” said Ashley Zehnder, Ph.D., Chief Executive Officer and co-founder of Fauna Bio. “By studying how hibernating mammals achieve remarkable feats of metabolic regulation—including dramatic, healthy weight cycling—we are uncovering therapeutic targets that have eluded traditional discovery approaches.”

The Convergence™ AI platform analyzes genomic data from over 450 mammal species, including more than 60 hibernators, integrating this comparative biology with human patient data to identify disease-relevant targets. The platform’s proprietary Graph Neural Network enables rapid evaluation and prioritization of novel targets across multiple therapeutic modalities.

“We are pleased to advance this collaboration into its next phase,” continued Zehnder. “This achievement reflects the deep scientific expertise of both teams and reinforces the value of our unique approach to drug discovery.”

About Fauna Bio

Fauna Bio is a biotechnology company improving human health by leveraging animal genomics and extreme mammal biology. The company’s proprietary Convergence™ platform integrates comparative genomic analyses across hundreds of mammal species with human disease data to identify novel therapeutic targets and develop transformative medicines. By studying animals that naturally resist disease—including hibernators that exhibit remarkable metabolic resilience—Fauna Bio translates these discoveries into innovative therapies for patients in need. The company is based in Emeryville, California. For more information, visit www.faunabio.com.

Contacts

Direct media inquiries to:

(510) 545-3945

media@faunabio.com

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

Pentixapharm Holding AG

/ Key word(s): Annual Report

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026 (news with additional features)

19.03.2026 / 10:14 CET/CEST

The issuer is solely responsible for the content of this announcement.


Pentixapharm Holding AG – FY 2025 Review & Management Outlook

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026.
During a conference call on Thursday, March 26, 2026, at 10:00 a.m., CEO Dr. Dirk Pleimes and CBO Henner Kollenberg will present the financial results for the 2025 fiscal year, a review of key operational developments and milestones, and an outlook on Pentixapharm’s clinical and strategic priorities.
 

  • Conference call on March 26, 2026, at 10:00 a.m. CET

To participate in the conference call, please register via the following link:
Registration for Pentixapharm Holding AG – FY 2025 Review & Management Outlook

About Pentixapharm Holding AG
Pentixapharm is a biopharmaceutical company with advanced clinical trials in the field of radiotherapeutics. Headquartered in Berlin, the company develops precision medicine diagnostics and therapeutics in the fields of oncology and cardiology with the aim of sustainably improving patient care.
 
For further information about Pentixapharm Holding AG please visit www.pentixapharm.com.
 
 


Additional features:

File: JA 2025 Einladung Earnings Call_PTX_ENG


19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2294404

 
End of News EQS News Service

2294404  19.03.2026 CET/CEST

Viromed Medical AG: Anna Heinen appointed to the Supervisory Board

Viromed Medical AG

/ Key word(s): Personnel

Viromed Medical AG: Anna Heinen appointed to the Supervisory Board

19.03.2026 / 09:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG: Anna Heinen appointed to the Supervisory Board

Rellingen, March 19, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has appointed a new member to its Supervisory Board. Anna Heinen was appointed to the Supervisory Board by court order. She succeeds Frank Otto, who resigned from the Supervisory Board for personal reasons.

Dr. Thomas Gutschlag, Chairman of the Supervisory Board of Viromed Medical AG, states: “I am very pleased that we have gained a qualified Supervisory Board member in Anna Heinen with proven expertise in the areas of corporate strategy, transformation, and governance. With her experience, she will provide important impetus for the further development of our company. At the same time, on behalf of the entire Supervisory Board and the Management Board, I would like to express our sincere thanks to Frank Otto for his commitment over the past three years. He provided valuable support to Viromed during the company’s crucial growth phase.”

Anna Heinen has been a member of the Supervisory Board of Smartaxxess Operation AG, a fintech company focused on planning, valuation and financing for small and medium-sized enterprises, since 2022. She is also a qualified Supervisory Board member according to Deutsche Börse standards, as well as being a member of ARMID – Aufsichtsräte Mittelstand in Deutschland e.V. Professionally, Ms. Heinen has been responsible for the corporate strategy of e-fellows.net GmbH & Co. KG, an HR service provider owned by McKinsey & Company and Zeitverlag, for many years. Since 2023, she has also supported medium-sized companies regularly in succession and transformation processes as an independent management consultant.

 

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

 

Contact Viromed

E-Mail: kontakt@viromed-medical.de

 

Press contact

E-Mail: viromed@kirchhoff.de


19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
EQS News ID: 2294118

 
End of News EQS News Service

2294118  19.03.2026 CET/CEST

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Evotec SE

/ Key word(s): Miscellaneous

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

19.03.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


 
  • Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer
  • Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinoma
  • Study start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of ‘molecular glues’ being advanced as treatment options for different cancer types
  • Validates Evotec’s high-performance multi-omics screening and AI-supported data analytics and drug design capabilities
 

Hamburg, Germany, March 19, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.

Initiation of the first‑in‑human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue’ candidate jointly generated through Evotec’s powerful and fully integrated drug discovery platform. This platform combines high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities, selectively prompting cancer cells to eliminate disease‑driving proteins. As a result of this clinical progression, Evotec will receive a milestone payment of $10 million.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec said:

“In this unique collaboration, we follow a systematic approach to discovering molecular glues with tremendous therapeutic potential. Together with Bristol Myers Squibb, and building on Evotec’s PanOmics and PanHunter platforms, we have identified a broad portfolio of high-potential molecular glue drug candidates that are now beginning to enter clinical development. The initiation of this Phase 1 clinical trial marks the first clinical milestone in the strategic protein degradation partnership with BMS. Molecular glues have the potential to address significant unmet medical need not only in oncology, but far beyond, by targeting previously undruggable, disease-causing proteins and thereby aiming to reshape future standards of care.“

BMS-986506 was developed under the strategic protein degradation partnership between Evotec and Bristol Myers Squibb. The collaboration combines PanOmics, Evotec’s high-performance multi-omics screening platform as well as PanHunter, Evotec’s AI-supported data omics analytics platform with BMS’s industry-leading library of CELMoDs™ agents. Initiated in 2018 and expanded in 2022, the collaboration is continuing to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.

About Molecular Glue Degraders

Conventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins “undruggable”. Conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.

Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and degradation of the recruited protein. This event-driven mechanism of action significantly expands the range of the druggable proteome. The molecular glue is not degraded in the process and can trigger the degradation process many times over, thus leading to longer-lasting therapeutic effects.

About Evotec’s Strategic Collaboration with Bristol Myers Squibb in Molecular Glues

In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. BMS is a leader in this field based on its unique library of CELMoDs™ agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.

Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec’s leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec’s PanOmics data analysis platform PanHunter. It supports the integration and analysis of these data sets and thereby enables the selection of the most promising CELMoDs™ for further progression into lead optimization.

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com


19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
EQS News ID: 2293690

 
End of News EQS News Service

2293690  19.03.2026 CET/CEST

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair




BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

  • Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta

STOCKHOLM, March 19, 2026 (GLOBE NEWSWIRE) — BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced the appointment of highly respected industry leader Elaine Jones, PhD, as Chair of its Board of Directors. Elaine succeeds Ingelise Saunders, who will remain on the Board.

Elaine Jones is a distinguished biopharmaceutical executive, venture investor, and board leader, bringing more than two decades of experience shaping and scaling innovative life science companies. Over her career, she has served on more than 35 company boards and held senior roles across the global biotechnology ecosystem, including as Vice President of Venture Capital at Pfizer Ventures, where she oversaw strategic investments in companies aligned with Pfizer’s R&D priorities, and earlier in leadership roles at GSK’s corporate venture fund, SR One.

Her appointment marks an important inflection point for BOOST Pharma as it advances BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta (OI), also known as Brittle Bone Disease, toward Phase III clinical development. BT-101 has shown promising data in early clinical trials demonstrating reductions in fractures among affected children, supporting its potential as the first disease-modifying therapy for this severe rare condition.

Hans Schambye, Chief Executive Officer of BOOST Pharma, said: “Elaine’s unique combination of strategic insight, investment acumen and deep board leadership experience will be invaluable as we prepare BT‑101 for late‑stage development and drive the Company into its next phase of growth. I would also like to express my sincere thanks to Ingelise Saunders for her outstanding service as Chair. She has guided BOOST through critical milestones and challenging periods with exceptional commitment, and we are delighted she will continue contributing as a Board Director.”

Elaine currently serves on the boards of CytomX Therapeutics, HBM Healthcare Investments AG, and NextCure, is Chair of Mironid, and is also a member of the Board of the Novartis Venture Fund.

Dr. Elaine Jones, incoming Chair of BOOST Pharma, commented: “BOOST Pharma has the scientific vision, clinical ambition, and highly experienced team to position the company for long-term success. BT‑101 is an especially compelling program, with the potential to meaningfully improve the lives of children living with osteogenesis imperfecta. I look forward to supporting BOOST as it advances this promising therapy into late‑stage development and builds further value for patients, partners, and investors.”

As BOOST Pharma enters this next stage of growth, the Company will meet with partners and investors at key industry events this spring, including BIO-Europe Spring and LSX World Congress Europe, where CEO Hans Schambye will participate in expert panel discussions.

For more information, please contact:

Optimum Strategic Communications
Zoe Bolt | Vareen Outhonesack | Nellie Stephens

Tel: +44 (0) 20 388 296 21

Email: boostpharma@optimumcomms.com

About BOOST Pharma

BOOST Pharma ApS is a clinical‑stage biotechnology company developing novel, first‑in‑class off-the-shelf stem cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead program, BT‑101, is an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta, a severe rare bone disorder, and has received Orphan Drug Designation in both the U.S. and Europe. BT‑101 is currently advancing toward a planned Phase III clinical trial.

BOOST is backed by a strong syndicate of life‑science investors, including Industrifonden, Karolinska Development, and Sound Bioventures, who support the Company’s strategy focused on high‑impact science, capital‑efficient development, and clear pathways to market. The Company is led by a team with deep experience in biotech innovation, clinical execution, and value creation. For further information, please visit https://boostpharma.com/.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also known as Brittle Bone Disease, is a rare and devastating genetic disorder characterized by extremely fragile bones, reduced bone mass, and frequent fractures, often beginning in infancy. Individuals with OI may experience dozens to hundreds of fractures over a lifetime, along with loose joints, weakened teeth, and significant skeletal deformities. Beyond bone fragility, people living with OI frequently face muscle weakness, fatigue, curved bones, scoliosis, respiratory complications, early‑onset hearing loss, and short stature, all contributing to substantial impacts on overall health and quality of life.

There are currently no FDA or EMA‑approved disease‑modifying therapies for OI; existing management is purely supportive, aimed at reducing fracture risk and preserving mobility. OI affects an estimated 1 in 15,000 people globally, underscoring the urgent need for safe and effective treatments.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d6a4ee5-196c-4500-b705-394f7e47eec1

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment




SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.

SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term success across multiple modalities. The company continues to expand its small molecule and peptide businesses while reinforcing its commitment to viral vector development and manufacturing, and believes this three-business-unit approach positions SK pharmteco as a versatile CDMO partner for biopharma companies managing increasingly diverse pipelines, from established therapeutics to advanced therapies.

To advance this strategy, $100 million USD will be deployed to reinforce and expand capabilities across the company’s viral vector business, including its centers of excellence in King of Prussia, Pennsylvania, and Corbeil-Essonnes, France. SK pharmteco is prioritizing operational excellence with a focus on further maturing quality systems, optimizing process performance, and advancing technology transfer while enabling innovation across its global network to deliver more reliable development, late-stage, and commercial execution.

“Our strategy is built on the strength of three essential business units: small molecules, peptides, and viral vectors,” said Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco. “As the industry evolves, our partners need a CDMO that combines specialized expertise, technical sophistication, and operational reliability across modalities. This commitment supports our continued efforts to strengthen our viral vector business while advancing the broader capabilities, quality, and commercial readiness that customers expect across our global network.”

By advancing its three-business-unit strategy, SK pharmteco is strengthening its position as a differentiated global CDMO, combining the reliability and scale of established small molecule manufacturing, the specialized capabilities of its peptides business, and the advanced expertise required to support the development and manufacture of viral vector-based therapies.

About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company’s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market. Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com

Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting

Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting




Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting

ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine

London, UK, 19 March 2026 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been selected to give an oral presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting, taking place from 19 March to 21 March, in New Orleans, USA.

Dr. Joshua Hirsch, Neurointerventionalist, Professor at Harvard Medical School, Board Member of ASIPP and medical advisor to Persica will be presenting PP353 data from the Company’s Phase 1b Modic Trial published in The Lancet’s eClinicalMedicine in February 2026. The data show that PP353 – Persica’s targeted, non-opioid therapeutic approach – demonstrated clinically meaningful and statistically significant improvements in pain and disability in patients with cLBP and Modic type 1 changes.

The company will also present an e-poster which will be on display throughout the meeting and published in an upcoming issue of the Pain Physician journal.

Duncan McHale, Chief Medical Officer of Persica Pharmaceuticals, said: “ASIPP is a leading meeting for companies working in pain, and we’re proud that Persica’s abstract ranked in the top five and was selected for an oral presentation this year – an additional strong validation of our science. PP353 is an innovative approach that targets the underlying disease of chronic Low Back Pain rather than just the symptoms. We’re excited to share the progress we’re making towards our goal of delivering a novel treatment option for the millions suffering with this debilitating condition that causes severe disability, as well as putting a significant burden on healthcare systems.”

Dr. Joshua Hirsch, Neurointerventionalist, Professor at Harvard Medical School and Board Member of ASIPP, added: “Chronic low back pain remains difficult to treat and places a substantial burden on patients and healthcare systems worldwide. Many patients cycle through existing therapies with limited relief, underscoring the urgent need for new treatment approaches. A targeted, non-opioid therapy like PP353, that addresses the underlying cause of disease, has the potential to meaningfully improve how we treat this large patient population and I look forward to seeing PP353 advance into Phase 3 studies.”

Presentation details:

Presentation Date and Time Presentation Title
Friday March 20th, 12:00pm CT PP353 Intradiscal Linezolid for Modic Type 1 cLBP: A Double‑Blinded, Sham‑Controlled Phase 1b Study

To read the full paper: Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial

For further information:        
ICR Healthcare – Tracy Cheung, Chris Welsh, Emily Johnson        
persica@icrhealthcare.com

About Persica Pharmaceuticals        
Persica Pharmaceuticals is a clinical-stage biotechnology company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic type 1 changes. Modic changes are a sign of inflammation, visible on Magnetic Resonance Imaging (MRI) scans at the vertebral endplate adjacent to a degenerate lumbar disc, and which can extend into the body of the vertebrae. PP353 is a patented, targeted intradiscal antibiotic injection that is delivered directly to the site of infection. It is a non-opioid treatment which addresses an underlying cause of cLBP, rather than just the symptoms, and removes the need for extended duration of antibiotic treatment.

About PP353        
PP353 (intradiscal linezolid) is a suspension of linezolid powder in a thermosensitive vehicle, which is liquid at room temperature but increases in viscosity when injected into the site of infection and warmed to body temperature. This increase in viscosity prevents PP353 from leaking out of the degenerate disc into adjacent tissues during injection. PP353 also contains a radio-opaque dye, which allows the physician to use image guidance to make sure the gel is positioned correctly in the target disc on injection.

About chronic Low Back Pain with Modic Type 1 changes        
Chronic Low Back Pain (> 6 months) with Modic Type 1 changes is a common patient subgroup. These patients are readily identifiable on MRI and typically suffer from moderate to severe persistent pain and disability with limited relief from the current standard of care – physiotherapy and analgesia including opioids – with a prevalence of four million patients in the US, EU and Japan. Current treatment options provide only limited short-term relief or involve invasive, irreversible nerve ablation, which does not address the underlying cause of pathology, i.e., a suspected disc infection.

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment




Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment

The Group’s strategy and recent acquisitions enable upselling to higher-value markets

  • +8% turnover growth to €4.9 billion (-5% Like-For-Like basis, LFL1) and +13% Current EBITDA increase to €612 million, driven by the pharmaceutical and food specialties businesses.
  • +54 bps increase in Current EBITDA margin to 12.6% showing the value of recent strategic acquisitions and the resulting evolution of the Group’s portfolio.
  • Excluding the cash impact of the IFF Pharma Solutions acquisition, Free Cash-Flow landed at €301 million.
  • In 2025, Roquette maintained a robust balance sheet with a strong liquidity position and a net debt to combined Current EBITDA ratio of 3.48x versus 3.72x end of June.
  • Early 2026, Roquette launched ‘Shift & Lead’, a comprehensive company plan to reinforce its competitiveness, strengthen its market position, and provide long-term value creation to all stakeholders.

Lille – March 19th, 2026 – Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its 2025 full-year results, following the approval of its financial statements by the Board of Directors.

Thierry Fournier, CEO of Roquette, commented on the period: “We are seeing the significant benefits of our recent strategic moves and acquisitions, which allow Roquette to offer a more comprehensive portfolio and reinforce our focus on high-value products and markets. Despite a very challenging environment characterized by soft demand, overcapacity, and persistent geopolitical and economic uncertainties, our specialty products remain the key driver of our resilient performance in 2025.”

Regarding the Health & Pharma Solutions Business Unit, the strong performance from new product lines coming from the recent IFF Pharma Solutions acquisition mitigated the effect of softer demand and destocking in the starch and capsules markets, with notable gains from cellulose and alginates products for oral dosage. 

The Nutrition & Bioindustry Business Unit delivered strong results in food specialties, even in the face of sluggish markets and intense competition, with higher demand in food and nutrition, particularly for fiber and protein products. Combined with increased unit prices and lower variable costs, this has resulted in significant margin improvements for specialty products.

Collectively, these achievements strengthened Roquette’s market position and delivered resilient results in a complex landscape, affirming how the company’s strong foundations allow it to continue growing in a volatile and highly competitive environment. “Throughout 2026, we will maintain our commitment to operational excellence, innovation, financial discipline, and cash generation. Guided by our purpose: “Together, we turn the potential of nature into the essentials of life”, we are determined to become the global leader in sustainable plant-based solutions, driven by outstanding innovation and strong client partnerships that shape the future of nutrition, health and bioindustry. By defining and executing ‘Shift & Lead’, our comprehensive company plan, we will reinforce our competitiveness, strengthen our market position, and build for long-term value creation for all our stakeholders”, concluded Thierry Fournier.

FULL YEAR 2025 CONSOLIDATED KEY FIGURES2

(in millions of euros) 2024 2025 Var. (%) Var. LFL (%)
Turnover 4,495 4,877 +8% -5%
Current EBITDA 540 612 +13% -14%
Current EBITDA margin 12.0% 12.6% +54bps -115bps
Net result 61 (265) – –
Adjusted net result (a) 114 70 -39% –
Free Cash-Flow IFRS
(excluding IFF Pharma Solutions) (b)
275 301 – –
         
(in millions of euros) 2024 2025    
Net debt IFRS 237 2,390    
Restated leverage ratio
(Net debt IFRS / Combined Current EBITDA) (c)
0.44x 3.48x    

(a) Excluding non-recurring items amounting to €335 million (€44 million in FY 24), associated taxes and one-off deferred tax charges in the USA.
(b) IFF Pharma Solutions acquired on May 1st, 2025
(c) Combined Current EBITDA includes IFF Pharma Solutions estimated Current EBITDA over the last twelve months.

FINANCIAL PERFORMANCE

EXPANDED PORTFOLIO DRIVES PERFORMANCE IN A HIGHLY CHALLENGING ENVIRONMENT

In 2025, Roquette operated in a particularly demanding environment marked by soft global demand, overcapacity in certain commodity markets, intensified competition, and continued geopolitical and macroeconomic uncertainties. Against this backdrop, the Group delivered resilient full-year results, demonstrating the relevance of its strategic repositioning toward higher-value markets and products.

Full-year turnover reached €4,877 million, up 8% compared to 2024, given the integration of IFF Pharma Solutions from May 1st, 2025. On a Like-for-Like basis, sales were down 5%, reflecting continued pressure in commodity markets and softer demand in selected pharmaceutical segments.

Current EBITDA increased by +13% to €612 million, representing a margin of 12.6%, up +54 basis points compared to 2024. On a Like-for-Like basis, Current EBITDA was down -14% (margin down -115 basis points), reflecting competitive pressures, partially offset by disciplined cost management and a favorable product mix. Margin improvement was primarily driven by the contribution of IFF Pharma Solutions, consolidated since May 1st, 2025, strong performance in food specialties, continued execution of the Group’s competitiveness program and a favorable cost environment compared to the peak inflationary period of 2022–2023.

Reported net loss for 2025 amounted to €265 million, mainly reflecting the impact of non-recurring items, including the acquisition and integration costs related to IFF Pharma Solutions (€87 million) and impairment charges (€231 million). Excluding non-recurring items and associated taxes, adjusted net result stood at €70 million.

FREE CASH-FLOW GENERATION

Consolidated figures – full year
(in millions of euros)
2024 2025
Operating Cash-Flow 352 352
Variation in working capital requirement 157 212
Investments paid (234) (263)
Free Cash-Flow IFRS 275 301
IFF Pharma Solutions Acquisition – (2 403)
Free Cash-Flow IFRS (after acquisition) 275 (2 102)

Excluding the impact of the IFF Pharma Solutions acquisition, the Group generated positive free cash-flow of €301 million in 2025, supported in particular by solid operating cash-flow and a positive contribution from working capital requirement (WCR).

WCR remained broadly stable at 19.0% of sales in 2025, compared with 18.9% at year-end 2024. This evolution reflects higher sales following the integration of IFF Pharma Solutions and, to a lesser extent, higher inventory levels, which were contained thanks to proactive and efficient inventory management initiatives.

The Group maintained a strong focus on WCR management throughout the year, including the use of receivables factoring at year-end, which contributed approximately €128 million to free cash-flow generation in 2025. This measure helped to preserve financial flexibility and support the Group’s investment capacity.

Total investments amounted to €263 million in 2025, compared with €234 million in 2024, reflecting the Group’s continued commitment to innovation, industrial excellence and capacity expansion in higher-value segments, thereby supporting its long-term profitable growth potential.

PERFORMANCE BY BUSINESS UNIT

HEALTH & PHARMA SOLUTIONS – STRONG PERFORMANCE FROM NEW PRODUCT LINES MITIGATES MARKET PRESSURE

(in millions of euros) FY 24 FY 25 Var. (%) Var. LFL (%)
Sales 823 1 391 +69% -8%
Eliminations (int. sales) (13) (119)    
Current EBITDA 236 349 +48% -18%
Current EBITDA margin % 28.7% 25.1% -364bps -311bps

The full-year performance of the Health & Pharma Solutions Business Unit was primarily driven by the integration of IFF Pharma Solutions, which generated a positive perimeter effect, and by strong momentum across specialty excipient technologies, including cellulose, alginates and polymers. Polyox achieved record sales over the year, reflecting sustained demand in high-value applications.

The enlarged portfolio has significantly strengthened Roquette’s position as a global drug delivery partner, offering a comprehensive range of excipient technologies including starch, cellulose, alginates, and capsules, while further rebalancing the Group’s mix toward higher-value markets and products.

However, the business operated in a complex market environment marked by soft demand and destocking in the capsules segment, intense competition on polyols from Chinese players, particularly in Europe, and pricing pressure in selected product categories. Lower volumes in capsules were partially offset by variable cost improvement.

Despite these headwinds, the contribution of IFF Pharma Solutions and the resilience of high-value excipient technologies supported overall commercial and operating performance. The IFF Pharma Solutions acquisition nurtured profitability, confirming its strong strategic relevance and placing Roquette on a sustained value creation trajectory.

NUTRITION & BIOINDUSTRY – SPECIALTIES HOLDING UP AS COMMODITIES REACH CYCLICAL LOW

(in millions of euros) FY 24 FY 25 Var. (%) Var. LFL (%)
Sales 3 847 3 750 -3% -4%
Eliminations (int. sales) (277) (245)    
Current EBITDA    303    263 -13% -10%
Current EBITDA margin % 7.9% 7.0% -88bps -51bps

The Nutrition & Bioindustry Business Unit demonstrated resilience with strong performance in food specialties despite a particularly challenging market environment.

Commodity demand for starch and starch derivatives reached historically low levels in late 2025, reflecting structural overcapacity and subdued market conditions. Against this backdrop, Roquette continued to gain market share in starch and starch derivatives, particularly in Europe, while facing strong price pressure in Europe linked to the decline in sugar prices and intense competition in India.

The Food & Nutrition segment delivered strong performance, benefiting from higher demand across specialty applications, including proteins and fibers, especially in Europe, as well as increased unit prices and lower variable costs. As a result, specialty products delivered significant margin improvement within the Business Unit, partially offsetting persistent pressure in commodity segments.

BALANCE SHEET

(in millions of euros) FY 24 H1 25(a) FY 25
Financial debt IFRS 1,791 3,320 3,185
Cash & cash equivalents and financial investments 1,554     465 795
Net debt IFRS     237 2,854 2,390
Restated leverage ratio (Net debt IFRS / Combined Current EBITDA) (b) 0.44x 3.72x 3.48x
Gross debt towards financial institutions (cf. Appendix 5) 1,641 3,072 2,801

(a) Non-audited H1 25 consolidated accounts
(b) Combined Current EBITDA includes IFF Pharma Solutions estimated EBITDA over the last twelve months.

Acquisition-driven leverage, commitment to maintaining a strong investment-grade credit profile

Net financial debt amounted to €2,390 million at year-end 2025, compared with €2,854 million at half-year 2025. This decrease reflects the intra-year seasonality of working capital requirement and strong free cash-flow generation. The restated leverage ratio (Net debt IFRS / Combined Current EBITDA) improved to 3.48x, compared to 3.72x at the end of June 2025, demonstrating the initial effects of the IFF Pharma Solutions acquisition and disciplined financial management in the second half of the year.

Roquette has defined a clear deleveraging trajectory and targets a return to a leverage ratio between 2.3x and 2.7x by 2027, consistent with its commitment to maintaining a strong investment-grade credit profile (target BBB). Under the “Shift & Lead” strategic plan, the Group is committed to disciplined capital allocation and enhanced cash generation. The plan focuses on operational excellence and margin expansion, supporting a structural improvement in free cash-flow generation and progressive deleveraging.

Successful post-acquisition refinancing

The bridge financing put in place to fund the acquisition of IFF Pharma Solutions has been fully refinanced through the issue by the Group of two US Private Placements (USPP). In November 2025, Roquette issued a USD 450 million USPP with maturities ranging from 2032 to 2040. In December 2025, a second €200 million USPP was issued, with maturities ranging from 2032 to 2037. These transactions further diversified the Group’s investor base and funding sources across EUR and USD markets, while significantly extending its debt maturity profile.

The acquisition of IFF Pharma Solutions has been financed through a diversified and balanced combination of instruments, including:

  • A €0.6 billion hybrid Eurobond (accounted for 100% as equity under IFRS);
  • A €0.6 billion senior Eurobond, maturing in 2031;
  • Approximately €0.6 billion equivalent in EUR and USD US Private Placements (USPP), ultimately maturing in 2040;
  • Approximately €0.6 billion equivalent in EUR and USD amortizing term loans, maturing in 2029.

This successful refinancing demonstrates the Group’s continued access to capital markets following the acquisition and reflects investors’ confidence in Roquette’s credit fundamentals and long-term strategy.

Strong liquidity and balanced maturity profile

As of December 31st, 2025, gross financial debt amounted to €3.2 billion. The Group benefits from a well-balanced and staggered maturity profile, with an average debt maturity of 6.1 years and no material refinancing concentration in the short term. Available liquidity totaled €1,558 million at year-end, including €763 million of undrawn committed credit facilities, €795 billion of undrawn commercial paper programs and available cash. This solid liquidity position provides the Group with financial flexibility to support its operations, ongoing integration of IFF Pharma Solutions and future growth initiatives.

STRATEGY AND OUTLOOK

Roquette expects the current challenging market environment to continue. To sustain competitiveness, financial performance, and long-term value creation in these conditions, the company launched in January 2026 a comprehensive strategic company plan, by the name of ‘Shift & Lead’.

‘Shift & Lead’ builds on Roquette’s strong foundations as a diversified and resilient company, supported by family ownership and a long‑term vision, to strengthen operational excellence, innovation, financial discipline, and cash generation. This strategic plan aims to sustain growth and fully unlock the value of the company’s recent acquisitions, which enhance its leadership positions and open new pathways for profitable expansion.

Delivering this roadmap requires disciplined capital allocation and a robust financial structure. The Group remains committed to maintaining a strong investment-grade credit profile, ensuring continued access to financing to support investments in its people, industrial assets and innovation capabilities.

Supported by this solid plan and its diversified enlarged portfolio, Roquette enters 2026 with confidence in the resilience of its business model and the relevance of its strategic positioning to weather current challenges and emerge stronger.

The press release can be viewed on the Group’s website www.roquette.com.

Status of the accounts:
Audit procedures on the consolidated accounts are in progress.

About Roquette

Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.

The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.

A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.

Together, we turn the potential of nature into the essentials of life.

Discover more about Roquette here.

Press contacts:
Brunswick
Antoine Parison
+33 (0) 7 88 72 28 95
aparison@brunswickgroup.com

Roquette
Corporate Communications
Susannah Duquesne
Susannah.duquesne@roquette.com

Financial Communications
Cécile Masurel
cecile.masurel@roquette.com

DISCLAIMER – Certain statements contained in this press release may contain forecasts that specifically relate to future events, trends, plans or objectives. By nature, these forecasts involve identified and unidentified risks and uncertainties and may be affected by many factors likely to give rise to a significant discrepancy between the actual results and those indicated in these statements. The group does not undertake to publish an update or revision of these forecasts, or to communicate on new information, future events or any other special circumstance. The amounts presented in this presentation have been rounded to the nearest hundred/unit, which may result in slight discrepancies in totals. Thus, the financial data is provided for informational purposes only and may not exactly match the figures in the consolidated financial statements.

FINANCIAL INFORMATION – This press release and Roquette’s full regulated information are available on the Group’s website: Roquette website

GLOSSARY

To measure its performance, the Group uses certain financial indicators that are not defined by IFRS standards. These indicators are used in the operational monitoring of the Group’s activities and its financial communication (press releases, financial presentations, etc.).

Alternative performance indicators Definitions and reconciliation with IFRS indicators
Current EBITDA The Group is now focusing on Current EBITDA, in line with the calculation of financial leverage.
Current EBITDA corresponds to the Current operating income minus Amortizations and Depreciations aggregate in the consolidated income statement, excluding the IFRS 3 effect related to the inventory step-up due to the Purchase Price Allocation (“PPA”) in 2025.
This indicator includes, in particular, gains and losses on disposals of fixed assets, the impacts of insurance proceeds and investment grants, and excludes the effects of write-downs on current assets, which are part of the Current operating income.
Operating Cash-Flow Operating cash flow corresponds to the Cash-Flow generated by operating activities (from the consolidated cash flow statement), plus the change in net working capital, the unrealized financial result on operating receivables and payables, the “net impairment of current assets” (impacts the operating cash flow) and “other reconciling items”.
Free Cash-Flow Free Cash-Flow corresponds to cash flow after investments (from the cash flow statement derived from the consolidated accounts), to which is added the Change in other current assets (for Short-term investments mentioned in Note 16 “Current and non-current financial assets”, which are included in the aggregate “Net debt”), the change in other non-current assets (for long-term investments and receivables related to equity interests and loans mentioned in Note 16 “Current and non-current financial assets”, which are included in the aggregate “Net debt”), the change in the scope of the Qualicaps debt mentioned in Note 22. 2a for the 2023 financial year and “Other reconciliation items”.
Net debt Net debt corresponds, on the basis of the consolidated accounts, to non-current financial liabilities, current financial liabilities, minus cash and cash equivalents, as well as Other current assets (for Short-term investments mentioned in Note 16 “Current and non-current financial assets”, which are included in the aggregate “Net debt”) and Other non-current assets (for Long-term investments and Receivables related to investments and loans mentioned in Note 16 “Current and non-current financial assets”, which are included in the aggregate “Net debt”).

APPENDIX 1 – INCOME STATEMENT

(in thousand euros)   2024 2025
Turnover   4 494 743 4 876 525
Cost of goods sold and external charges   (3 180 538) (3 410 745)
Personnel costs   (754 888) (868 088)
Taxes   (28 363) (29 964)
Amortization and depreciation   (287 635) (355 483)
Other operating income   29 893 30 463
Other operating expenses   (20 984) (11 074)
Current operating income   252 228 231 633
Non-recurring items   (68 366) (320 850)
Operating income   183 862 (89 217)
Cost of net financial debt   (52 435) (90 511)
Other financial result and expenses   (12 396) (19 512)
Financial result   (64 830) (110 023)
Income from companies accounted for by the equity method   (5 086) (3 916)
Pre-tax profit   113 946 (203 157)
Income tax   (53 379) (62 139)
Net income   60 566 (265 296)
Profit or loss, Group share   59 556 (266 426)
Net income from non-controlling interests   1 010 1 130
Profit or loss (Group share) per share   20,27 (90,69)

APPENDIX 2 – COMPREHENSIVE INCOME STATEMENT

(in thousand euros)   2024 2025
Net income   60 566 (265 296)
Change in translation adjustments   37 701 (145 319)
Gains and losses on hedging derivatives   52 673 (80 014)
Tax impact   (11 568) 18 970
Items that may be reclassified subsequently to P&L   78 806 (206 363)
Revaluation of net liabilities (assets) of defined benefit plans   1 030 9 608
Tax impact   340 (2 477)
Items that may not be reclassified subsequently to P&L   1 370 7 131
Other comprehensive income, net of tax   80 176 (199 232)
Overall result   140 742 (464 528)
Including Group share   139 715 (465 636)
Including non-controlling interests   1 028 1 108

APPENDIX 3 – BALANCE SHEET

(in thousand euros)   2024 2025
Goodwill   281 567 1 019 792
Intangible fixed assets   280 715 1 223 042
Tangible fixed assets   2 373 499 2 492 243
Investments in associates   7 870 12 843
Non-current financial assets   71 352 74 637
Other non-current assets   37 592 38 686
Deferred taxes   76 748 56 015
Non-current assets   3 129 342 4 917 258
Inventories   835 580 1 081 963
Accounts receivable and similar accounts   631 571 670 868
Tax assets   23 549 11 595
Current financial assets   1 199 211 1 582
Other current assets   237 482 189 677
Cash and cash equivalents   309 214 765 876
Current assets   3 236 607 2 721 560
Total assets   6 365 949 7 638 818

    2024 2025
Share capital   8 813 8 813
Reserves   2 725 752 2 499 942
Net income   59 556 (266 426)
Own shares   (3 632) (3 573)
Hybrid bonds   603 314 628 294
Equity Group share   3 393 803 2 867 051
Equity non-controlling interests   5 699 8 978
Equity   3 399 502 2 876 029
Non-current financial debt   1 367 194 2 485 479
Non-current provisions   863 21 473
Non-current employee benefits   73 432 110 462
Other non-current liabilities   67 862 73 840
Deferred taxes   177 948 256 330
Non-current liabilities   1 687 299 2 947 584
Current financial debt   423 691 699 523
Current provisions   14 871 18 068
Current employee benefits   4 715 5 254
Accounts payable and similar accounts   448 652 625 286
Tax liability   9 802 29 001
Other current liabilities   377 416 438 073
Current liabilities   1 279 148 1 815 205
Total liabilities   6 365 949 7 638 818

APPENDIX 4 – CASH FLOW STATEMENT

(in thousand euros)   2024 2025
Net income   60 566 (265 296)
Amortization and depreciation (excluding current assets)   289 032 355 918
Impairment recognized in non-recurring items   – 231 108
Income taxes (current and deferred)   53 379 62 139
Other items   22 113 5 910
Gross cash flow   425 091 389 779
Change in net working capital requirement   150 649 217 206
Income tax paid   (61 013) (37 009)
Net cash flow from operating activities   514 727 569 976
Acquisition of consolidated companies, acquired cash flow deducted   5 848 (2 403 132)
Purchase of tangible and intangible assets   (261 430) (277 733)
Sales of fixed assets   1 466 20 714
Change in fixed assets suppliers   4 380 (4 884)
Financial investments   (1 222 670) 1 212 820
Impact of disposals   14 437 –
Net cash flow from investment activities   (1 457 969) (1 452 215)
Dividends paid to shareholders of the Group   (88 651) (53 630)
Dividends paid to minority interests   (469) (291)
Hybrid bonds (debt and coupons)   596 034 (8 286)
Proceeds from borrowings   758 845 1 854 435
Repayment of borrowings   (91 004) (941 963)
Net change in other debts   (97 410) 363 554
Net cash flow from financing activities   1 077 344 1 213 820
Impact of foreign currency exchange rate fluctuations   17 205 26 080
Change in cash flow   151 307 357 661
Change in cash flow   151 307 357 661
Opening cash balance   156 351 307 658
Closing cash balance   307 658 665 319
Including bank loans   (1 556) (100 557)
Including cash and cash equivalents   309 214 765 876

APPENDIX 5 – GROSS DEBT TOWARDS FINANCIAL INSTITUTIONS

This aggregate excludes bank loans, loan issue fees, lease debts and accrued interest, and therefore reflects nominal amounts of indebtedness to financial institutions (banks and investors).

(in thousand euros)

 

   
2024 2025
Bond loans 900 1 483
Term loan Qualicaps 410 360
Term Loan IFF EUR 0 275
Term Loan IFF USD 0 298
RCF drawn 184 16
Short-term bank overdraft drawn 45 0
Other bank loans 12 10
Bank loans 651 958
Negociable debt securities 90 360
Debts to financial institutions 1 641 2 801
Accrued interest 9 13
Transactional fees -8 -9
Bank overdrafts 2 101
Current rent debt (IFRS 16) 138 168
Other financial debt 10 111
Financial debt 1 791 3 185


1 Like-For-Like basis excludes exchange rates impact and perimeter variation.
2 The definition of the alternative performance indicators is provided in the appendices of this press release.